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Summary The disposition of 5-fluorouracil (FUra) was studied in 19 colorectal cancer patients dunrng
treatment with FUra and high-dose leucovorin (LV) with or without interferon x2a (IFN-a). All received LV
200 mg m- Iover 2 h. then FUra 400 mg m-2 over 5 min then FUra 400 mg m ' over 22 h. repeated on day 2.
on a 14 day cycle. Nine patients also received IFN-a 6 MU every 48 h, starting at least 2 weeks before the
study. Series of 14 blood samples were assayed for FUra by reversed-phase high-performance liquid
chromatography (HPLC). Minimum Akaike information criterion estimation was used to determine the
simplest effective pharmacokinetic model. This consisted of a single compartment with first-order (linear) and
Michaelis-Menten (non-linear) components to drug elimination. This model gave r' >0.98 in 19 20 data sets.
With the Michaelis constant (K,,) set at 15;LM. values were derived for the volume of distribution (Vd). the
maximum rate of non-linear elimination (V,,) and the first-order elimination rate constant (ki,). Mean
(± s.d.) values in control (no IFN-a) patients were: Vd 10.4 (± 1.9) 1 m-'. V,,. 182 (± 59) .tmol 1' h-' and
k1, 4.35 (± 0.58) h-'. No significant differences were detected in patients receiving IFN-a. in whom the
equivalent mean values were Vd 10.0 (±0.9)lm-2. V,,. 141 (±27)nmollI'h-' and kl, 3.% (±0.5)h-'.
Mean trapezoidal AUC0 _h was similar in the two groups (control patients 116 1M h. IFN- patients
125 limh). No significant correlations with renal or hepatic function were detected. These results, while not
inconsistent with previous reports of a reduced rate of FUra elimination at higher IFN-c doses. suggest that
any clinical effect of this moderate dose of IFN-a on FUra toxicity or activity is due to modulation at target
cells. not to pharmacokinetic interaction.
Recent years have seen intense efforts to improve the activity
of the pyrimidine analogue 5-fluorouracil (FUra) in the treat-
ment of colorectal cancer and other solid tumours. Strategies
have included novel administration routes and schedules (e.g.
hepatic artery infusion, protracted venous infusion) and the
exploitation of biochemical interactions with other drugs (e.g.
leucovorin; PALA).
Interferons (IFNs), though they have no useful single-
agent activity against colorectal cancer, nonetheless display
synergistic cytotoxic interactions with FUra against certain
human colorectal cancer models in vitro and in vivo (reviewed
by Wadler & Schwartz. 1990). A number of possible mechan-
isms of interaction have been proposed, including (with
different interferons in different tumour models) stimulation
by IFN of the metabolic pathway(s) leading to FUra activa-
tion (Schwartz et al., 1992), inhibition by IFN of adaptive
up-regulation of one of FUra's targets, thymidylate synthase
(Chu et al., 1990; Seymour et al., 1992), and enhancement by
IFN of FUra-induced DNA breaks (Houghton et al.. 1993).
Clinical interest in the FUra,IFN-a combination was stimu-
lated by a promising phase II trial of FUra and IFN-a in
patients with colorectal cancer (Wadler & Wiernik, 1990),
and although attempts to repeat this study have met with
lower response rates there is still a suggestion of a degree of
clinical interaction between the two agents. The modulatory
effect of IFN appears. in vitro, to be complementary to that
of leucovorin (LV) (Houghton et al., 1991), on which basis
several groups are investigating 'double modulation' in the
clinic, using FUra LV IFN-a combinations.
In addition to biochemical interactions at the target cell
demonstrable in vitro, it has been suggested that. in vivo, the
systemic pharmacokinetics of FUra is affected by concurrent
administration of IFN-a. The results from different studies
are conflicting: some report that IFN-a reduces the rate of
FUra elimination. with correspondingly increased plasma
concentrations and area under the concentration-time curve
(AUC) (Grem et al., 1991; Danhauser et al.. 1993). but
others show no such effect (Kreuser et al.. 1992; Pittman et
al., 1993; Sparano et al., 1993). FUra kinetics is complicated
by non-linearity, making it possible that different factors
operate at high or low ranges of FUra plasma concentration.
although no studies to date have addressed this question.
For FUra-IFN-a interaction to be clinically useful, the
cytotoxic synergy observed in tumour cell lines in vitro must
operate at the tumour cell level in vivo. On the other hand, if
IFN-a's only biological effect were to reduce FUra's rate of
plasma clearance, it may be nothing more than an expensive
and toxic alternative to giving more FUra. In this respect.
pharmacokinetic interaction may complicate our assessment
of the true clinical usefulness of the combination. It is
therefore important that clinical trials which aim to examine
the FUra IFN-a interaction should include an assessment of
FUra pharmacokinetics.
We report here a pharmacokinetic evaluation undertaken
in patients participating in a UK national randomised trial of
FUra LV with or without the addition of IFN-a [Medical
Research Council (MRC) trial CR04]. In contrast to previous
studies, FUra kinetics has been measured during both bolus
and infusional phases of FUra treatment. and analysed using
a non-linear pharmacokinetic model, in order to determine
the influence of IFN-a on FUra kinetics over the full range
of therapeutic concentrations.
Patients and methods
Patients
Following ethical committee approval. 19 consenting patients
were studied, all of whom had histologically proven colorec-
tal carcinoma not amenable to local treatment, no prior
treatment with FUra, Eastern Cooperative Oncology Group
(ECOG) performance status 0-2 and life expectancy > 3
months. Patients were invited to participate in the pharma-
cokinetic study only after one or more treatment cycles had
been given uneventfully. As shown in Table I, there were no
major differences in the characteristics of patients recruited
from the two treatment arms.
Because patients were participating in a randomised
therapy trial, it was not possible to use a crossover design to
compare matched cycles. Instead, all patients were studied
during just one cycle of their allocated treatment, with one
patient studied on two occasions, giving a total of ten phar-
macokinetic studies in each treatment arm. For normally
distributed variables, this study design gives 90% power to
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Table I Patient characteristics
FUraILV FUra/LV/IFN
Number 10 9a
Male:female 7:3 5:4
Age
Median 65 54
Range 23-71 37-68
Surface area 1.8 1.7
Median (range) (1.2-2.1) (1.4-2.2)
Hepatic dysfunctionb 5 4
Renal dysfunctionc 3 2
aOne patient studied twice, ten studies in total. bALP or AST
>2 x normal or bilirubin>25 gm. cCreatinine clearance<60ml
min-' (Cockroft estimate).
column ofApex ODS, 5 tLm. Detection was at 270 nm, using
an LDC Spectro-Monitor III variable-wavelength detector.
The run time for each sample was 9 min, FUra having a
retention time of 5.25 min.
Concentration was calculated in relation to peak area. The
detector response was linear up to 1.5 x I0- mol of injected
FUra, corresponding to a plasma level of 385jAM. The limit
of detection was 8 x 10-12 mol injected FUra, corresponding
to a plasma level of 0.2pJM. Overall day-to-day inter-assay
precision was calculated by extracting and analysing repli-
cates of spiked plasma at 1.8 and 46 JM, which produced
coefficients of variation of 9% and 7.5% respectively. Intra-
assay precision at 20JM was <4%.
detect a difference between the two groups of 1.5 x the co-
efficient of variation. This power was considered sufficient,
since an effect which is small in comparison with normal
inter-patient variability is unlikely to have a major clinical
impact.
Treatment
The chemotherapy regimen was that of de Gramont et al.
(1988), consisting of LV 200mg m2 over 2h, followed by
FUra 400mg m2 bolus injection over 5 min and, starting
simultaneously, FUra 400mgm-' in 2,000ml of 5% dext-
rose over 22 h. This whole regimen is repeated on day 2 and
is given on a 14 day cycle. All treatments were started at
II00h± ± h. Patients randomised to the IFN-c arm also
received recombinant human IFN-a2a (Roche Products, UK)
6 x 106 i.u., not adjusted for patient size, by s.c. injection on
alternate evenings through the whole cycle. Pharmacokinetic
profiles were obtained during the second or a subsequent
cycle of chemotherapy, on the first day of the cycle only.
Thus patients on IFN-a had received at least 2 weeks' treat-
ment, with the last in,iection 12-16h before the study.
Sampling
Blood was collected into lithium heparin tubes and plasma
was separated within 15 min in a chilled centrifuge, frozen in
liquid nitrogen and stored at -40-C until analysis. Samples
were obtained at the following times relative to the start of
the FUra bolus injection: time 0 (pre-FUra); 5 min (end of
bolus); 10, 15, 20, 30 and 45min; 1, 1, 2, 21, 3, 4, 8 and
22 h. The precise timing of each sample was recorded and
used for curve-fitting.
5-Fluorouracil assay
The reverse-phase HPLC assay for FUra was modified from
that of Christophidis et al. (1979). Plasma was first subjected
to organic extraction and back-extraction: to 0.5 ml plasma
was added 25jAl of 1 M sodium acetate (pH 4.8), 200Jll of
1.4 M ammonium sulphate and 7.5 ml of a mixture of diethyl
ether-propan-2-ol (80:20, v/v). After vortex mixing and
separation of the organic layer, FUra was back-extracted
into an aqueous phase of 0.5 ml of 0.05 M potassium
orthophosphate (pH 10.7). A 100#LI volume of this aqueous
phase was then acidified with 20 1l of 1 M orthophosphoric
acid, and 50;lI of this extract was used for chromatography.
Standard curves and controls were prepared by adding
known amounts of FUra, in the range 1-400 0AM, to pooled
blank plasma, then extracting alongside the unknown sam-
ples in the same way. All standards and controls were run
daily. Extraction efficiency, calculated by comparing ex-
tracted and unextracted standards, was 80%.
Chromatography was performed using an ACS model 351
solvent delivery system set at a flow rate of 0.7 mlmin'1,
using 0.05 M potassium dihydrogen orthophosphate as
mobile phase. A 2 cm precolumn of Spherisorb octadecyl
silane (ODS) 10;Lm was followed by the 15cm analytical
Pharmacokinetic analsis
Compartmental modelling was performed using TopFit ver-
sion 2.0 software (Heinzel et al., 1993). Regression weighting
was set at l/[FUra], and parameters were calculated relative
to body surface area. Non-linear pharmacokinetic modelling
was based upon the Michaelis-Menten equation:
-dC
dt
Vmox'C
Km +C
where C is the drug concentration, V. is the maximum
achievable rate of change and KM is the Michaelis constant,
equal to the drug concentration at which the rate of change
is half-maximum.
A technique of 'parametric parsimony' was employed to
select the simplest effective model. This method, described in
full by Yamaoka et al. (1978), uses the minimum Akaike
information criterion estimation (MAICE). The Akaike in-
formation criterion (AIC) is calculated as:
AIC=N In R,+2p
where N is the number of experimental data points, R, is the
residual weighted sum of squares and p is the number of
variable parameters in the model. The criterion is therefore a
measure of goodness of fit with a 'penalty score' for the
complexity of the model, the optimum model giving the
lowest AIC value.
Accordingly, each patient's data were fitted successively to
a series of compartmental models of increasing complexity,
and the AIC value calculated in each case. The six models
explored were:
(a) one compartment with first-order elimination;
(b) one compartment with non-linear (Michaelis-Menten)
elimination;
(c) one compartment with both first-order and Michaelis-
Menten elimination;
(d) two compartments with first-order elimination from the
central compartment;
(e) two compartments with Michaelis-Menten elimination
from the central compartment;
(f) two compartments with both first-order and Michaelis-
- Menten elimination from the central compartment.
The models are shown in schematic form in Figure 1.
Model (c) proved best overall, giving the optimum AIC in 10
of the 20 data sets, and second optimum for the remaining
sets. It was therefore selected as the optimum model for the
study and applied to all data sets for comparative
analysis.
Statistical analysis
Statistical calculations were performed using MiniTab soft-
ware. The normality of distribution of each pharmacokinetic
variable was tested using the Shapiro-Wilk method. Among
each of the two patient groups there was one 'outlier',
identified as a value lying more than five standard deviations
from the mean; in one case abnormally high volume of
distribution (Vd), in the other abnormally high linear elimina-
tion (kl,). Both patients had rapidly progressive disease on
treatment and death occurred within a few weeks of the726 M.T. SEYMOUR et al.
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Fgre 1 a-f. The six pharmacokinetic models tested by
MAICE. showing the number of patients data for which each
was the optimum model. C = central compartment: P = peri-
pheral compartment: L = linear elimination; MM = Michaelis-
Menten elimination. The rate of change of FUra concentration is
described by a series of differential equations and or the
Michaelis- Menten equation. In the optimum model (c). the rate
of change of concentration in C is given by:
dC _ V+ rn_xC +k dt k C+
where C is the FUra concentration. k1 is the first-order elimina-
tion rate constant. I , and Km are the Michaelis-Menten con-
stants and ko is the infusion rate. Full descriptions of the non-
linear models (b). (c). (e) and (f) are given in Heinzel et al.
(1993).
study. These two patients' data were excluded from the
analysis in their entirety. Following this, comparison of para-
metric variables between the two groups of patients was
made using the two-(independent) sample t-test. The effects
of renal function, alkaline phosphatase and aspartate trans-
aminase on pharmacokinetic parameters were each assessed
using two-stage regression, correcting for the effect of treat-
ment.
Results
Plasma FUra fell during the 60 min after bolus injection.
then reached steady-state plasma concentration after 1.5-2 h
of FUra infusion. Visual comparison of the geometric (log-
transformed) mean data curves in Figure 2 shows that there
is no substantial difference in FUra plasma levels between
those patients receiving FUra V alone and those also
receiving IFN-a. Mean total AUCO h,h, calculated using the
linear trapezoidal method. is 1 16 JLM h for patients receiving
FUra, LV alone and 125 JIM h for those also receiving IFN-a
(P = 0.38). No consistent circadian rhythm was noted during
the infusion phase. although the timing of samples was not
selected to examine this phenomenon.
Model selection
The data show clear evidence of the non-linear disposition of
FUra. The fall in plasma [FUra] during the first hour
appears to follow a simple first-order exponential (Figure 2);
however, in every case there is wide disparity between the
apparent rate of FUra clearance during this phase (566 ±
124 ml min-', mean ± s.d.) and the subsequent rate of FUra
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Figure 2 Plasma FUra profiles. Geometric (i.e. log-transformed)
mean and standard deviation at each time point for patients
receiving FUra LV alone (0. n = 9) or with interferon (0.
n = 9). Dotted lines are computer fits to these mean data. using
the one-compartment linear + non-linear model illustrated in
Table I (c) (lower line = FUra LV: upper line= FUra LV IFN-
1x).
clearance during steady-state infusion (1717 ± 410 ml min ')
Consequently. it is impossible to describe the data using a
linear pharmacokinetic model.
Figure 1 shows the six models tested using MAICE. as
described in the Patients and methods section. In 10 of the 20
patients' data sets, model (c) was optimum fit, defined as the
lowest AIC value. In some patients, more complex models
(two distribution compartments and non-linear ± linear
elimination) could be justified by MAICE, although in each
case model (c) still gave a good fit, with r2> 0.985. For no
patient was a purely linear model (a. d) satisfactory.
Michaelis constant
If, during curve fitting, all variables are allowed to float'
simultaneously, the estimated KM for the geometric mean
control data is determined as 11.3I1M. However, modelling
individual patient data in this free way produces proportional
fluctuations of KS,, and V,, which make between-patient
comparison impossible. Indeed, with a single bolus/infusion
administration it is not possible to determine the KM for each
patient independently, so it is necessary to use a fixed value
for KM in this model. Collins et al. (1980), looking at a range
of dose schedules, found a K,, value of 15 9AM to give
optimum fits to patient data. Interestingly, this value
appeared to be corroborated 5 years later when Naguib et al.
(1985), measuring the in vitro kinetics of the enzymes of
FUra catabolism, determined the KM of human dihydro-
pyrimidine dehydrogenase (DPD) for FUra to be 149iM. For
these reasons, a fixed Km of 159iM was used for this
study.
Model application - effect ofinterferon
Each patient's data were fitted to derive values for volume of
distribution (Vd), maximum non-linear elimination rate (V,,)
and first-order elimination rate constant (kl,,). With the
exception of the two excluded outlier patients, good fits were
obtained with individual patient data during both bolus and
infusion phases. with weighted regression coefficients in the
range r2 = 0.985-0.998.
The companrson of FUra LV alone and FUra LVjIFN-a
patients is shown in Table II. The Shapiro-Wilk test shows
that each variable is normally distributed, so parametric
statistics have been used. No statistically significant differ-
ences are found between the two patient groups. The widest
difference in mean values occurs for V., but inter-patient
variability is greatest for this parameter, so the power to
detect a difference is reduced. Thus the data are not inconsis-
tent with a reduction of up to 48% in V, after IFN-x
treatment. On the other hand, Vd and kle show little inter-
patient variability, and the data are able to exclude a true
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Table n FUra pharmacokinetic parameters in patients receiving FUra LV or FUra LV IFN-a
FUra LV control (n = 9) FEra LV IFN-r (n = 9) 95% CI for
Coefficient of Coef cient of P-value IF.iV-x IFN-x control
Mfean s.d. variation (%) Mean s.d. variation (%) vs control ratio
AUC0O _. (Jum h-) 115.7 24.8 21 125.2 18.9 15 0.38 0.89-1.27
Vd (lm 2) 1039 1.89 18 10.00 0.94 9 0.58 0.81-1.11
V,,, (JLM h'-) 181.8 58.7 32 141.3 26.7 19 0.09 0.52-1.04
kh, (h-') 4352 0.575 13 3.961 0.513 13 0.15 0.78-1.04
Table HII Effect of IFN-a on FUra kinetics - previous studies
Reference FUra schedule n LV IF.V-u dose Significant effect on
(corr. 1.7,rn FL'ra pharmacokinetics
Grem et al. (1991) bolus 6 + 5MU o.d.
6 + 8.5 MU o.d. -
6 + 17MMU o.d. +
Schuller et al. (1992) bolus 10 - 5MU t.i.w. +
10 + 5 MU t.i.w. -
Kreuser et al. (1992) 4h inf. 10 + 5MU o.d.
Danhauser et al. (1993) 120h inf. 21 - 0.2-25 MU o.d. +
Pittman et al. (1993) 120h inf. 26 - 9MU t.i.w.
Lindley et al. (1990) PI 9 - 3.5-10 MU o.d. +
Sparano et al. (1993) PI 26 - 8.5 MU t.i.w.
PI. protracted ambulatory infusion.
difference of more than 18% and 22% respectively in these
two parameters. Using partial area predictions, the linear
elimination route accounts for >90% of the total drug
clearance during the initial hour after FUra bolus. However.
the non-linear route accounts for >55% of total clearance
during the steady-state infusion.
Organfunction
Two-step regression was used to assess the effect of organ
function on each of the pharmacokinetic parameters after
correction for any effect of interferon. No significant correla-
tions were found for serum alkaline phosphatase, serum
aspartate transaminase or estimated creatinine clearance
(using the formula of Cockcroft & Gault, 1976).
Discuss
We have not been able to demonstrate any effect of IFN-c.
at 6 MU on alternate days, upon the pharmacokinetics of
FUra. The power of the study is, of course, limited by its
size: however, we are able to exclude any effect which is large
in comparison with inter-patient variability. This finding is
contrary to some, but not all, previous reports.
The bolus-plus-infusion FUra schedule used in this study
has permitted the development of a relatively simple
mathematical model for the disposition of FUra over a wide
range of plasma concentrations. As a purely mathematical
tool, its elements do not directly represent physiological drug
disposition processes. For example, in this model the non-
linear route accounts for only a minority of FUra elimination
during the bolus phase, although Coustere et al. (1991) have
shown, using plasma, urinary and biliary catabolite modell-
ing, that the dihydropyrimidine dehydrogenase (DPD) cata-
bolic pathway is responsible for 55% of FUra clearance after
a 500 mg m-2 bolus injection.
By contrast, Collins et al. (1980) described an operational
model, with linear elimination set at the glomerular filtration
rate (representing renal clearance of unchanged drug) and a
Michaelis-Menten route representing drug metabolism.
Applying a similar approach to the current data, a fit is
obtained for most patients only when a very capacious peri-
pheral compartment is introduced, with kl.2>>k,,: in prac-
tice, an additional linear elimination pathway.
With these reservations about the interpretation of para-
meters in the mathematical model used in this study, it might
nonetheless be expected that changes in DPD activity would
be primarily reflected as changes in the V,n,. In a recent
study, Yee et al. (1992) found that DPD activity in patients'
peripheral blood mononuclear cells fell by 50% after 4 days
of IFN-a treatment. In the current study, no statistically
significant difference in Vm,,,, was found, although the wide
variability of this parameter means that a reduction of up to
48% could have been missed.
Previous studies of FUra,'IFN-a pharmacokinetic interac-
tion have yielded inconsistent results (see Table III). All have
used a paired cycle design, measuring plasma levels during
FUra (or FUra,'LV) treatment, then adding IFN-a and re-
sampling. This has the advantage of correcting for inter-
patient variability, but may introduce systematic error when
treatments are always given in the same order. The studies
have involved either bolus or infusional regimens, not both,
and have assumed linear kinetics, deriving values for appar-
ent plasma clearance (Cl) and apparent half life.
Two studies involve bolus FUra regimens. Grem et al.
(1991) measured the kinetics of bolus FUra (with high-dose
LV) before and after IFN-a2a at 3, 5 and 10 MU m-2 day-'.
and reported a significant reduction of 25% in FUra clear-
ance at the highest IFN--x dose. The results of Schuiller et al.
(1992) are provocative: bolus FUra kinetics was measured in
ten patients, first on FUra alone, then on FUra with IFN-
a2b and finally on triple therapy including high-dose LV. A
linear two-compartment model was applied, and the authors
found significantly decreased mean FUra clearance and in-
creased mean AUC for FUra/'IFN-a compared with FUra
alone. These changes appeared to be reversed when LV was
introduced, leading to postulation that IFN-a decreases
FUra's metabolic clearance and that its effect is negated by
leucovorin. However, the inter-patient variability was greater
for FUra/IFN-a than for the other data sets, with three
patients having end-of-bolus plasma levels 2-3 times greater
than the median. In the presence of non-linearity, this may
have produced artefactually low values for FUra 'clearance':
the conclusion of the study may have been different had an
appropriate non-linear model been used.
Turning to infusional regimens, an early abstract report of
dramatic elevation of FUra levels within 1 h of administering
IFN-a2b has yet to be published in full (Lindley et al.. 1990).
More recently Danhauser et al. (1993). assuming that steady-
state FUra plasma concentration had been reached after
50 min (five 'half-lives') of FUra continuous infusion, cal-
culated Cl%5 from a single sample then introduced IFN-a2b
after 16-21 h. There was a statistically significant decrease in728 M.T. SEYMOUR et al.
C1S after adding IFN-a; however the complete lack of
IFN-a dose relationship over the range 0.1-15.0 MU m'
suggests that the difference may have been caused by the
timing of samples rather than by IFN-a. Sparano et al.
(1993) made a more thorough assessment of steady-state
kinetics, using at least seven samples over 48 h. before intro-
ducing IFN-a2a. Care was taken to correct for diurnal vanra-
tion in FUra kinetics by performing cosinor analysis before
and after IFN--m addition. No effect of IFN-x on FUra
kinetics was seen. Similarly, Pittman et al. (1993). in the only
study to use a random-order crossover design. found no
effect of IFN-a2a on [FUraL in 26 patients. Kreuser et al.
(1992). also using multiple samples, measured drug levels
during a 4 h infusion of 500 mg m-2 FUra before and after
the addition of IFN-a2b: again. no difference was found.
In conclusion IFN-a. at 6 MU on alternate days. has no
significant effect on the pharmacokinetics of FUra. The cur-
rent study has the advantages of exaamining both bolus and
infusional phases of FUra administration, and of using a
non-linear pharmacokinetic model which avoids the artefac-
tual variations in apparent clearance which arise with the
inappropriate use of linear modelling. Review of the litera-
ture suggests that, at higher doses of IFN-a around 10 MU
m-2 day-', FUra elimination may be reduced, probably
through decreased DPD activity. However, some of the
studies which have suggested an effect should be interpreted
with reservation, and there is no conclusive published
evidence for a pharmacokinetic interaction at lower doses of
IFN-a.
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